[
  {
    "ts": null,
    "headline": "INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance",
    "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=91a95dd7f51ad4d62d1ecd885bde2795b9ca71701921586f1d24c7739c8507dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747133052,
      "headline": "INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance",
      "id": 134410621,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=91a95dd7f51ad4d62d1ecd885bde2795b9ca71701921586f1d24c7739c8507dd"
    }
  }
]